Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy

Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk

(2021) Steven E. Nissen et al.   JAMA Cardiology

A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs

(2021) Takahito Doi et al.   EUROPEAN HEART JOURNAL

The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl

(2021) Ph Gabriel Steg et al.   EUROPEAN HEART JOURNAL

Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid

(2020) R. Preston Mason et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies

(2020) Brian Olshansky et al.   EUROPEAN HEART JOURNAL SUPPLEMENTS

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk

(2020) Stephen J. Nicholls et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT

(2019) Deepak L. Bhatt et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Anticytokine Agents

(2019) Paul M Ridker   CIRCULATION RESEARCH

Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles

(2019) Deepak L. Bhatt et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events

(2018) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

(2018) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

From C-Reactive Protein to Interleukin-6 to Interleukin-1

(2016) Paul M Ridker   CIRCULATION RESEARCH

Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome

(2014) Michelle L. O’Donoghue et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies

(2013) Harold E. Bays et al.   American Journal of Cardiovascular Drugs

Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)

(2012) Christie M. Ballantyne et al.   AMERICAN JOURNAL OF CARDIOLOGY

Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial)

(2011) Harold E. Bays et al.   AMERICAN JOURNAL OF CARDIOLOGY

High-Sensitivity C-Reactive Protein and Lipoprotein-Associated Phospholipase A 2 Stability Before and After Stroke and Myocardial Infarction

(2009) Mitchell S.V. Elkind et al.   STROKE

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE